Best Grants for Preschools in Northern Mariana Islands

The NEA Arts and Artifacts Domestic Indemnity Program provides museums and cultural institutions in the U.S. with financial protection against loss or damage to significant artworks during exhibitions. Established in 1975 and expanded in 2007, the program aims to enhance public access to art by minimizing insurance costs. Managed by the National Endowment for the Arts, it involves thorough evaluations by expert panels to ensure eligibility and compliance, facilitating the safe display of invaluable cultural treasures.

The Chemical Countermeasures Research Program (CCRP) Initiative aims to support vital research on the harmful effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids, including fentanyl and its combinations. This funding opportunity encourages studies that enhance understanding and mitigation strategies for these substances, focusing on both immediate and long-term health impacts. Applications are due by 5:00 PM local time, with optional Letters of Intent accepted 30 days prior to the proposal deadline.

The NIH StrokeNet initiative invites applications for clinical trials and biomarker studies aimed at stroke treatment, recovery, and prevention. This funding opportunity encourages collaborative projects that validate promising interventions and scientific aims within the NIH StrokeNet framework. Key deadlines for submissions span from February 2025 to November 2026, with support provided by the National Coordinating Center and Regional Coordinating Centers to ensure efficient study implementation and participant recruitment.

The NCI Pathway to Independence Award (K99/R00) supports talented postdoctoral researchers in transitioning to independent faculty positions. This program provides essential NCI research funding to facilitate the development of competitive, independent research careers. Applications are due by 5:00 PM local time of the applicant's organization, emphasizing the importance of timely submissions for prospective awardees.

This grant opportunity aims to reduce sleep health disparities through non-pharmacological interventions. It supports research that examines sleep as a modifiable factor influencing health outcomes among populations facing health disparities. The initiative highlights the importance of promoting sleep health in various communities, ensuring equitable access to resources and interventions. Deadlines for applications span from October 2024 to June 2027, allowing multiple opportunities for researchers to apply and contribute to this vital area of health research.

The Research Opportunities for New and At-Risk Investigators (R01 Clinical Trial Optional) program invites applications that promote workforce diversity in health-related sciences. This initiative encourages researchers from underrepresented backgrounds to propose independent research projects in alignment with NIH's mission. Important deadlines for standard and renewal applications range from February 2025 to November 2027. This effort aims to enhance diversity and inclusion within the scientific community.

The Academic Research Enhancement Award (AREA) supports small-scale research at institutions that receive limited NIH funding, emphasizing biomedical research for undergraduate students. This program aims to enhance the research environment and provide valuable experiences for students. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million in NIH support over four of the last seven years. This funding opportunity encourages investigator-initiated minimal risk clinical trials to advance NIH missions.

The National Institutes of Health (NIH) is inviting applications for the Screening, Brief Intervention, and Referral to Treatment or Prevention (SBIRT/P) program. This funding opportunity aims to explore innovative methods for addressing alcohol, tobacco, and other drug use among adults facing health disparities. The initiative seeks research proposals that will implement and evaluate SBIRT/P strategies in collaboration with healthcare and community partners. This approach is crucial for enhancing public health and ensuring effective interventions.

The NCCIH Multi-Site Feasibility Clinical Trials (R01) invites applications for clinical trials focused on mind and body interventions. This program emphasizes the need for multisite feasibility studies to gather essential data for future efficacy trials. The initiative is designed to enhance public health by addressing gaps in scientific knowledge related to the delivery, recruitment, and data collection of integrative health approaches. Deadlines for submissions range from February 2025 to October 2026.

This funding opportunity invites applications for investigator-initiated clinical trials that deliver complementary and integrative health interventions remotely or via mobile health technologies. Emphasizing no in-person contact, the trials should demonstrate feasibility, safety, and potential clinical benefits. A Plan for Enhancing Diverse Perspectives is required for submission, and applicants are encouraged to consult with NCCIH contacts before applying. Deadlines for submissions range from February 2025 to October 2026.

The NEI Postbaccalaureate Opportunities in Vision Science (POVS) Research Education Program aims to enhance the training of a diverse workforce in biomedical research. This NIH-funded initiative focuses on providing intensive, hands-on research experiences for recent college graduates from various backgrounds, preparing them for doctoral programs in biomedical fields. The program encourages participation from individuals without prior research opportunities in vision sciences, fostering a nationally recruited cohort for substantial impact in the field.

The Feasibility Clinical Trials of Mind and Body Interventions grant aims to support trials that examine complementary and integrative health approaches for high-priority NCCIH research topics. This opportunity seeks to gather essential data for designing future efficacy studies, focusing on aspects such as feasibility, acceptability, and recruitment strategies. The goal is to bridge gaps in scientific knowledge and enhance public health impact through rigorous clinical research. Applicants are encouraged to contact NCCIH representatives for guidance.

The FY26 Breast Cancer Research Program's Transformative Breast Cancer Consortium Award fosters significant collaborations that aim to revolutionize care for individuals affected by breast cancer. This award supports a multidisciplinary consortium of leading scientists, clinicians, and advocates to tackle major challenges in breast cancer research. Proposals must address at least one of the program's overarching challenges and demonstrate a transformative impact that cannot be achieved by individual investigators alone.

The FY26 Hearing Restoration Research Program (HRRP) Focused Research Award (FRA) aims to enhance drug discovery and therapeutic development for hearing restoration following military-related auditory injuries. The award supports preclinical and clinical studies aligned with HRRP focus areas. It features two funding levels, including a Partnering Principal Investigator option, and evaluates proposals based on research rationale, strategy, impact, and personnel. Notably, it excludes funding for clinical trials, tinnitus, and vestibular research.

The NIH Research Evaluation and Commercialization Hubs (REACH) program aims to facilitate the translation of biomedical discoveries into marketable products to enhance patient care. By funding five new academic entrepreneurship hubs, NIH will provide essential resources such as funding, mentorship, and expertise in product development. These hubs will address high-priority technologies and foster public-private partnerships, ultimately supporting the goals of federal research initiatives and addressing local health needs in underserved areas.

The FY26 Neurofibromatosis Research Program's Exploration-Hypothesis Development Award encourages innovative, high-risk research concepts in neurofibromatosis (NF). This award aims to support groundbreaking studies that will pave the way for future scientific inquiries. Proposals should present a well-defined, testable hypothesis grounded in sound scientific rationale. While preliminary data is encouraged, it is not a prerequisite for submission, allowing researchers to explore novel paradigms and perspectives in NF research.

The NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) aims to support innovative research in behavioral and social interventions for dental, oral, and craniofacial conditions. This funding opportunity includes a milestone-driven planning phase of up to 2 years, with potential transition to implementation for an additional 5 years, facilitating comprehensive trial development and assessment.

The Academic Research Enhancement Award (AREA) supports small-scale research grants for institutions with limited NIH funding, emphasizing biomedical research experiences for undergraduates. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million in NIH support over the past seven years. This initiative aims to enhance the research environment at these institutions, fostering student involvement in research activities.

The NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22) aims to support postdoctoral fellows from underrepresented backgrounds in transitioning to tenure-track positions. This award provides essential funding for salary and research support for three years, enabling candidates to establish independent biomedical careers. Key deadlines for applications range from February 2025 to October 2027, ensuring ample opportunity for eligible researchers to secure funding for their career development.

The NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22) supports early-career independent researchers to transition from postdoctoral positions to assistant professor roles. This award aims to enhance diversity in the biomedical workforce, offering funding opportunities for innovative research projects. Key application deadlines span from February 2025 to October 2027. The program is funded by the US Department of Health & Human Services, specifically the National Institutes of Health (NIH).

The NIH Career Transition Award (K22) supports exceptional basic and clinical investigators in developing independent research skills through a two-phase program: an intramural appointment at NIH followed by support at an extramural institution. This award specifically aids NINDS intramural neurologist and neurosurgeon scientists in transitioning to independent academic faculty roles, fostering the engagement of clinician-scientists in both funded scientific research and clinical practices.

The NIH Career Transition Award (K22) aims to support outstanding clinician-scientists in developing independent research skills. This grant facilitates a two-phase program, starting with an intramural appointment at the NIH followed by support at an extramural institution. Designed for NINDS intramural neurologist- and neurosurgeon-scientists, it helps them transition to independent academic faculty roles, enabling them to engage in funded scientific research alongside clinical activities.

The NCI CURE Mentored Clinical Scientist Research Career Development Award (K08) aims to support individuals with clinical doctoral degrees in developing research careers that address national health-related needs. This program focuses on enhancing the research capabilities of underrepresented clinical scientists in cancer research, including health disparities. Awardees receive protected time for supervised research training, preparing them to compete for future research project grants. Key deadlines for applications span from February 2025 to October 2027.

The NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) grant invites applications for mid-phase clinical trials focusing on natural products such as botanicals and dietary supplements. It aims to advance scientific knowledge by determining optimal dosing and patient responses. Applicants must provide preliminary data demonstrating bioavailability and measurable impacts on target engagement. This initiative will not support efficacy trials for cancer treatments and encourages early contact with NCCIH scientific contacts.

The NCCIH Natural Product Early Phase Clinical Trial Award supports innovative clinical trials of natural products, such as botanicals and dietary supplements, with a strong scientific basis. Applications are encouraged to explore optimal delivery methods and combinations with other treatments. Funding is available for up to three years to assess the impact on target engagement and clinical outcomes, aiming to translate basic science findings into practical clinical applications.

The NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33) invites research proposals for early phase clinical trials of natural products, including botanicals and dietary supplements, emphasizing scientific validity for further testing. Applicants may receive up to three years of funding for pharmacokinetics and bioavailability studies, with potential for an additional three years to evaluate clinical outcomes. This initiative aims to optimize natural product delivery through innovative study designs.

The FY26 Neurofibromatosis Research Academy – Scholar Award supports early-career independent investigators focusing on neurofibromatosis research. Scholars are required to be within 10 years of their terminal degree and must designate a Career Guide for mentorship, fostering collaboration. This initiative aims to advance impactful research and develop skilled researchers in a supportive environment, addressing critical areas of emphasis in neurofibromatosis research.